| dc.description |
Jiang, X., Biopharmaceutical Lab., College of Life Science, Northeast Agricultural University, 600 Changjiang Road, Harbin, 150030, China; Liu, S., Biopharmaceutical Lab., College of Life Science, Northeast Agricultural University, 600 Changjiang Road, Harbin, 150030, China; Wang, Y., Biopharmaceutical Lab., College of Life Science, Northeast Agricultural University, 600 Changjiang Road, Harbin, 150030, China, Shanghai Hailu Biological Co., Ltd, Shanghai, 200000, China; Zhang, R., Biopharmaceutical Lab., College of Life Science, Northeast Agricultural University, 600 Changjiang Road, Harbin, 150030, China; Opoku, Y.K., Biopharmaceutical Lab., College of Life Science, Northeast Agricultural University, 600 Changjiang Road, Harbin, 150030, China, Department of Biology Education, Faculty of Science Education, University of Education, Winneba, Ghana; Xie, Y., Biopharmaceutical Lab., College of Life Science, Northeast Agricultural University, 600 Changjiang Road, Harbin, 150030, China; Li, D., Biopharmaceutical Lab., College of Life Science, Northeast Agricultural University, 600 Changjiang Road, Harbin, 150030, China, Jiangsu Kanion Pharmaceut CO LTD, State Key Lab New Tech Chinese Med Pharmaceut Pro, Lianyungang, Jiangsu, China; Ren, G., Biopharmaceutical Lab., College of Life Science, Northeast Agricultural University, 600 Changjiang Road, Harbin, 150030, China, Biopharmaceutical Teaching and Research Section, College of Life Science, Northeast Agricultural University, 600 Changjiang Road, Harbin, 150030, China |
en_US |
| dc.description.abstract |
Currently, insulin is commonly used in the clinical management of canine diabetes. However, it must be injected preprandially causing much inconvenience to the owners. Therefore, the development of long-acting hypoglycemic agents has attracted much attention in the scientific community. This study aimed to investigate the long-acting hypoglycemic effect of canine fibroblast growth factor 21 (cFGF-21) in diabetic dogs. Diabetic dogs were administered with cFGF-21, polyethylene glycol-modified cFGF-21 (PEG-cFGF-21), or insulin once a day, once every 2, 3, or 4 days subcutaneously. The results showed that cFGF-21 and PEG-cFGF-21 maintained blood glucose comparable to normal levels for 2 and 3 days respectively while insulin maintained the blood glucose for only 2 h after a single injection. After treatment with cFGF-21, oral glucose tolerance test (OGTT) was significantly improved with glycosylated hemoglobin (HbA1c) close to the normal levels. In addition, cFGF-21 significantly repaired islet ? cells, increased insulin content, and protected the pancreas from streptozotocin-induced injury. Furthermore, cFGF-21 exhibited both antioxidant and anti-inflammatory properties in the pancreas. We conclude, therefore, that cFGF-21 and PEG-cFGF-21 can maintain blood glucose comparable to normal levels for 2 and 3 days respectively after a single dose. The long-acting efficacy of cFGF-21 can be attributed to improvement in oxidative stress and the reduction of inflammation in the pancreas. � 2020, Springer-Verlag GmbH Germany, part of Springer Nature. |
en_US |